The Role of CD4 T Cell Help in CD8 T Cell Differentiation and Function During Chronic Infection and Cancer

키워드

참고문헌 (192)

1. Castellino F, "Cooperation between CD4+ and CD8+ T cells : when, where, and how", Annu Rev Immunol, 24, pp.519~540 (2006)
2. Borst J, "CD4+ T cell help in cancer immunology and immunotherapy", Nat Rev Immunol, 18, pp.635~647 (2018)
3. Bedoui S, "CD4+ T-cell help amplifies innate signals for primary CD8+ T-cell immunity", Immunol Rev, 272, pp.52~64 (2016)
4. Calabro S, "Differential intrasplenic migration of dendritic cell subsets tailors adaptive immunity", Cell Reports, 16, pp.2472~2485 (2016)
5. Gerner MY, "Dendritic cell and antigen dispersal landscapes regulate T cell immunity", J Exp Med, 214, pp.3105~3122 (2017)
6. Bachem A, "Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells", J Exp Med, 207, pp.1273~1281 (2010)
7. Hor JL, "Spatiotemporally distinct interactions with dendritic cell subsets facilitates CD4+ and CD8+ T cell activation to localized viral infection", Immunity, 43, pp.554~565 (2015)
8. Eickhoff S, "Robust anti-viral immunity requires multiple distinct T cell-dendritic cell interactions", Cell, 162, pp.1322~1337 (2015)
9. Joffre OP, "Cross-presentation by dendritic cells", Nat Rev Immunol, 12, pp.557~569 (2012)
10. Ferris ST, "cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity", Nature, 584, pp.624~629 (2020)
11. Bennett SR, "Help for cytotoxic-T-cell responses is mediated by CD40 signalling", Nature, 393, pp.478~480 (1998)
12. Schoenberger SP, "T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions", Nature, 393, pp.480~483 (1998)
13. Grewal IS, "The role of CD40 ligand in costimulation and T-cell activation", Immunol Rev, 153, pp.85~106 (1996)
14. Ridge JP, "A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell", Nature, 393, pp.474~478 (1998)
15. Morrison AH, "Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity", Proc Natl Acad Sci U S A, 117, pp.8022~8031 (2020)
16. Singh M, "Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain", Nat Commun, 8, pp.1447~ (2017)
17. Djureinovic D, "Agonistic CD40 antibodies in cancer treatment", Cancers(Basel), 13, pp.1302~ (2021)
18. Agarwal P, "Gene regulation and chromatin remodeling by IL-12 and type I IFN in programming for CD8 T cell effector function and memory", J Immunol, 183, pp.1695~1704 (2009)
19. Pipkin ME, "Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells", Immunity, 32, pp.79~90 (2010)
20. Janssen EM, "CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes", Nature, 421, pp.852~856 (2003)
21. Shedlock DJ, "Requirement for CD4 T cell help in generating functional CD8 T cell memory", Science, 300, pp.337~339 (2003)
22. Sun JC, "Defective CD8 T cell memory following acute infection without CD4 T cell help", Science, 300, pp.339~342 (2003)
23. Belz GT, "Compromised influenza virus-specific CD8+-T-cell memory in CD4+-T-cell-deficient mice", J Virol, 76, pp.12388~12393 (2002)
24. von Herrath MG, "CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge", J Virol, 70, pp.1072~1079 (1996)
25. Laidlaw BJ, "The multifaceted role of CD4+ T cells in CD8+ T cell memory", Nat Rev Immunol, 16, pp.102~111 (2016)
26. Williams MA, "Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells", Nature, 441, pp.890~893 (2006)
27. Provine NM, "Immediate dysfunction of vaccine-elicited CD8+ T cells primed in the absence of CD4+ T cells", J Immunol, 197, pp.1809~1822 (2016)
28. Wherry EJ, "Molecular signature of CD8+ T cell exhaustion during chronic viral infection", Immunity, 27, pp.670~684 (2007)
29. West EE, "Tight regulation of memory CD8+ T cells limits their effectiveness during sustained high viral load", Immunity, 35, pp.285~298 (2011)
30. Zajac AJ, "Viral immune evasion due to persistence of activated T cells without effector function", J Exp Med, 188, pp.2205~2213 (1998)
31. Snyder CM, "CD4+ T cell help has an epitope-dependent impact on CD8+ T cell memory inflation during murine cytomegalovirus infection", J Immunol, 183, pp.3932~3941 (2009)
32. Kemball CC, "The antiviral CD8+ T cell response is differentially dependent on CD4+ T cell help over the course of persistent infection", J Immunol, 179, pp.1113~1121 (2007)
33. Cardin RD, "Progressive loss of CD8+ T cell-mediated control of a gamma-herpesvirus in the absence of CD4+ T cells", J Exp Med, 184, pp.863~871 (1996)
34. Aubert RD, "Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection", Proc Natl Acad Sci U S A, 108, pp.21182~21187 (2011)
35. Battegay M, "Enhanced establishment of a virus carrier state in adult CD4+ T-cell-deficient mice", J Virol, 68, pp.4700~4704 (1994)
36. Matloubian M, "CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection", J Virol, 68, pp.8056~8063 (1994)
37. Fröhlich A, "IL-21R on T cells is critical for sustained functionality and control of chronic viral infection", Science, 324, pp.1576~1580 (2009)
38. Elsaesser H, "IL-21 is required to control chronic viral infection", Science, 324, pp.1569~1572 (2009)
39. Yi JS, "A vital role for interleukin-21 in the control of a chronic viral infection", Science, 324, pp.1572~1576 (2009)
40. Chevalier MF, "HIV-1-specific interleukin-21+ CD4+ T cell responses contribute to durable viral control through the modulation of HIV-specific CD8+ T cell function", J Virol, 85, pp.733~741 (2011)
41. Iannello A, "Dynamics and consequences of IL-21 production in HIV-infected individuals : a longitudinal and cross-sectional study", J Immunol, 184, pp.114~126 (2010)
42. Williams LD, "Interleukin-21-producing HIV-1-specific CD8 T cells are preferentially seen in elite controllers", J Virol, 85, pp.2316~2324 (2011)
43. Guo-Hua Feng, "HCV-Specific Interleukin-21+CD4+ T Cells Responses Associated with Viral Control through the Modulation of HCV-Specific CD8+ T Cells Function in Chronic Hepatitis C Patients", Molecules and Cells, 36(4), pp.362~367 (2013), 한국분자세포생물학회
44. Hale JS, "Distinct memory CD4+ T cells with commitment to T follicular helper-and T helper 1-cell lineages are generated after acute viral infection", Immunity, 38, pp.805~817 (2013)
45. Zander R, "Tfh-cell-derived interleukin 21 sustains effector CD8+ T cell responses during chronic viral infection", Immunity, 55, pp.475~493 (2022)
46. Fahey LM, "Viral persistence redirects CD4 T cell differentiation toward T follicular helper cells", J Exp Med, 208, pp.987~999 (2011)
47. Harker JA, "Late interleukin-6 escalates T follicular helper cell responses and controls a chronic viral infection", Science, 334, pp.825~829 (2011)
48. Crotty S, "T follicular helper cell differentiation, function, and roles in disease", Immunity, 41, pp.529~542 (2014)
49. Crotty S, "Follicular helper CD4 T cells(Tfh)", Annu Rev Immunol, 29, pp.621~663 (2011)
50. Greczmiel U, "Sustained T follicular helper cell response is essential for control of chronic viral infection", Sci Immunol, 2 (2017)
51. Cook KD, "T follicular helper cell-dependent clearance of a persistent virus infection requires T cell expression of the histone demethylase UTX", Immunity, 43, pp.703~714 (2015)
52. Linterman MA, "IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center responses", J Exp Med, 207, pp.353~363 (2010)
53. Zotos D, "IL-21 regulates germinal center B cell differentiation and proliferation through a B cell-intrinsic mechanism", J Exp Med, 207, pp.365~378 (2010)
54. Rasheed MA, "Interleukin-21 is a critical cytokine for the generation of virus-specific long-lived plasma cells", J Virol, 87, pp.7737~7746 (2013)
55. Wherry EJ, "Molecular and cellular insights into T cell exhaustion", Nat Rev Immunol, 15, pp.486~499 (2015)
56. Utzschneider DT, "T cell factor 1-expressing memory-like CD8+ T cells sustain the immune response to chronic viral infections", Immunity, 45, pp.415~427 (2016)
57. Snell LM, "CD8+ T cell priming in established chronic viral infection preferentially directs differentiation of memory-like cells for sustained immunity", Immunity, 49, pp.678~694 (2018)
58. Lin WW, "CD8+ T lymphocyte self-renewal during effector cell determination", Cell Reports, 17, pp.1773~1782 (2016)
59. He R, "Follicular CXCR5-expressing CD8+ T cells curtail chronic viral infection", Nature, 537, pp.412~428 (2016)
60. Im SJ, "Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy", Nature, 537, pp.417~421 (2016)
61. Leong YA, "CXCR5+ follicular cytotoxic T cells control viral infection in B cell follicles", Nat Immunol, 17, pp.1187~1196 (2016)
62. Zander R, "CD4+ T cell help is required for the formation of a cytolytic CD8+ T cell subset that protects against chronic infection and cancer", Immunity, 51, pp.1028~1042 (2019)
63. Hudson WH, "Proliferating transitory T cells with an effector-like transcriptional signature emerge from PD-1+ stem-like CD8+ T cells during chronic infection", Immunity, 51, pp.1043~1058 (2019)
64. Chen Z, "TCF-1-centered transcriptional network drives an effector versus exhausted CD8 T cell-fate decision", Immunity, 51, pp.840~855 (2019)
65. Kanev K, "Proliferation-competent Tcf1+ CD8 T cells in dysfunctional populations are CD4 T cell help independent", Proc Natl Acad Sci U S A, 116, pp.20070~20076 (2019)
66. Miller BC, "Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade", Nat Immunol, 20, pp.326~336 (2019)
67. Beltra JC, "Developmental relationships of four exhausted CD8+ T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms", Immunity, 52, pp.825~841 (2020)
68. Zander R, "Exhausted CD8+ T cells face a developmental fork in the road", Trends Immunol, 44, pp.276~286 (2023)
69. Guo X, "Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing", Nat Med, 24, pp.978~985 (2018)
70. Seo N, "Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4+ T-regulatory cells and systemic collapse of antitumour immunity", Immunology, 103, pp.449~457 (2001)
71. Antony PA, "CD8+ T cell immunity against a tumor", self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells, 2005, pp.174, 2591~2601
72. Tada Y, "Targeting VEGFR2 with ramucirumab strongly impacts effector", activated regulatory T cells and CD8+ T cells in the tumor microenvironment, 2018, pp.6, 106~
73. Jung-Ho Kim, "Regulatory T Cells in Tumor Microenvironment and Approach for Anticancer Immunotherapy", Immune Network, 20(1), pp.1~17 (2020), 대한면역학회[DOI]
74. Eberhardt CS, "Functional HPV-specific PD-1+ stem-like CD8 T cells in head and neck cancer", Nature, 597, pp.279~284 (2021)
75. Bauer CA, "Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction", J Clin Invest, 124, pp.2425~2440 (2014)
76. Joshi NS, "Regulatory T cells in tumor-associated tertiary lymphoid structures suppress anti-tumor T cell responses", Immunity, 43, pp.579~590 (2015)
77. Johnson DB, "Quantitative spatial profiling of PD-1", PD-L1 interaction and HLA-DR, Clin Cancer Res, pp.2018, 24[DOI]
78. Rodig SJ, "MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma", Sci Transl Med, 10 (2018)
79. Roemer MG, "Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic hodgkin lymphoma", J Clin Oncol, 36, pp.942~950 (2018)
80. Park IA, "Expression of the MHC class II in triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and interferon signaling", PLoS One, 12, pp.e0182786~ (2017)
81. Muranski P, "Th17 cells are long lived and retain a stem cell-like molecular signature", Immunity, 35, pp.972~985 (2011)
82. Végran F, "Th9 cells : a novel CD4 T-cell subset in the immune war against cancer", Cancer Res, 75, pp.475~479 (2015)
83. Cachot A, "Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer", Sci Adv, 7 (2021)
84. Quezada SA, "Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts", J Exp Med, 207, pp.637~650 (2010)
85. Muranski P, "Tumor-specific Th17-polarized cells eradicate large established melanoma", Blood, 112, pp.362~373 (2008)
86. Liotta F, "Frequency of regulatory T cells in peripheral blood and in tumour-infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma", BJU Int, 107, pp.1500~1506 (2011)
87. Hanagiri T, "Clinical significance of the frequency of regulatory T cells in regional lymph node lymphocytes as a prognostic factor for non-small-cell lung cancer", Lung Cancer, 81, pp.475~479 (2013)
88. Ben Khelil M, "Harnessing antitumor CD4+ T cells for cancer immunotherapy", Cancers(Basel), 14, pp.260~ (2022)
89. Schmidt A, "Molecular mechanisms of Treg-mediated T cell suppression", Front Immunol, 3, pp.51~ (2012)
90. Lucca LE, "Modulation of regulatory T cell function and stability by co-inhibitory receptors", Nat Rev Immunol, 20, pp.680~693 (2020)
91. Kumar P, "Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis", Semin Cancer Biol, 64, pp.29~35 (2020)
92. Kim MJ, "Deletion of PD-1 destabilizes the lineage identity and metabolic fitness of tumor-infiltrating regulatory T cells", Nat Immunol, 24, pp.148~161 (2023)
93. Knocke S, "Tailored tumor immunogenicity reveals regulation of CD4 and CD8 T cell responses against cancer", Cell Reports, 17, pp.2234~2246 (2016)
94. Marzo AL, "Tumor-specific CD4+ T cells have a major"post-licensing"role in CTL mediated anti-tumor immunity", J Immunol, 165, pp.6047~6055 (2000)
95. Wong SB, "Tumor-specific CD4+ T cells render the tumor environment permissive for infiltration by low-avidity CD8+ T cells", J Immunol, 180, pp.3122~3131 (2008)
96. Bos R, "CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes", Cancer Res, 70, pp.8368~8377 (2010)
97. Hashimoto M, "CD8 T cell exhaustion in chronic infection and cancer : opportunities for interventions", Annu Rev Med, 69, pp.301~318 (2018)
98. Baitsch L, "Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients", J Clin Invest, 121, pp.2350~2360 (2011)
99. Pauken KE, "Overcoming T cell exhaustion in infection and cancer", Trends Immunol, 36, pp.265~276 (2015)
100. Schietinger A, "Rescued tolerant CD8 T cells are preprogrammed to reestablish the tolerant state", Science, 335, pp.723~727 (2012)
101. Schietinger A, "Tolerance and exhaustion : defining mechanisms of T cell dysfunction", Trends Immunol, 35, pp.51~60 (2014)
102. Pauken KE, "Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade", Science, 354, pp.1160~1165 (2016)
103. Ribas A, "Cancer immunotherapy using checkpoint blockade", Science, 359, pp.1350~1355 (2018)
104. Wei SC, "Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade", Cell, 170, pp.1120~1133 (2017)
105. Ahmadzadeh M, "Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired", Blood, 114, pp.1537~1544 (2009)
106. Shin DS, "Primary resistance to PD-1 blockade mediated by JAK1", 2 mutations, 2017, pp.7, 188~201
107. Sen DR, "The epigenetic landscape of T cell exhaustion", Science, 354, pp.1165~1169 (2016)
108. Siddiqui I, "Intratumoral Tcf1+PD-1+CD8+ T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy", Immunity, 50, pp.195~211 (2019)
109. Kurtulus S, "Checkpoint blockade immunotherapy induces dynamic changes in PD-1-CD8+ tumor-infiltrating T cells", Immunity, 50, pp.181~194 (2019)
110. Alspach E, "MHC-II neoantigens shape tumour immunity and response to immunotherapy", Nature, 574, pp.696~701 (2019)
111. Kagamu H, "CD4+ T-cell immunity in the peripheral blood correlates with response to anti-PD-1 therapy", Cancer Immunol Res, 8, pp.334~344 (2020)
112. Martens A, "Increases in absolute lymphocytes and circulating CD4+ and CD8+ T cells are associated with positive clinical outcome of melanoma patients treated with ipilimumab", Clin Cancer Res, 22, pp.4848~4858 (2016)
113. Zuazo M, "Functional systemic CD4 immunity is required for clinical responses to PD-L1", PD-1 blockade therapy, 2019, pp.11, e10293~
114. Restifo NP, "Adoptive immunotherapy for cancer : harnessing the T cell response", Nat Rev Immunol, 12, pp.269~281 (2012)
115. Kochenderfer JN, "Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19", Blood, 116, pp.4099~4102 (2010)
116. Brentjens RJ, "Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias", Blood, 118, pp.4817~4828 (2011)
117. Rosenberg SA, "Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy", Clin Cancer Res, 17, pp.4550~4557 (2011)
118. Porter DL, "Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia", N Engl J Med, 365, pp.725~733 (2011)
119. Robbins PF, "Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1", J Clin Oncol, 29, pp.917~924 (2011)
120. Rosenberg SA, "Adoptive cell transfer as personalized immunotherapy for human cancer", Science, 348, pp.62~68 (2015)
121. Tran E, "Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer", Science, 344, pp.641~645 (2014)
122. Atrash S, "CAR-T treatment for hematological malignancies", J Investig Med, 68, pp.956~964 (2020)
123. Braendstrup P, "The long road to the first FDA-approved gene therapy : chimeric antigen receptor T cells targeting CD19", Cytotherapy, 22, pp.57~69 (2020)
124. Xu X, "Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies", Front Immunol, 10, pp.2664~ (2019)
125. Stock S, "Optimizing manufacturing protocols of chimeric antigen receptor T cells for improved anticancer immunotherapy", Int J Mol Sci, 20, pp.6223~ (2019)
126. Turtle CJ, "CD19 CAR-T cells of defined CD4+ : CD8+ composition in adult B cell ALL patients", J Clin Invest, 126, pp.2123~2138 (2016)
127. Moeller M, "Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection", Blood, 106, pp.2995~3003 (2005)
128. Guedan S, "ICOS-based chimeric antigen receptors program bipolar TH17", TH1 cells, 2014, pp.124, 1070~1080
129. Melenhorst JJ, "Decade-long leukaemia remissions with persistence of CD4+ CAR T cells", Nature, 602, pp.503~509 (2022)
130. Ostroumov D, "CD4 and CD8 T lymphocyte interplay in controlling tumor growth", Cell Mol Life Sci, 75, pp.689~713 (2018)
131. Ahrends T, "CD4+ T cell help confers a cytotoxic T cell effector program including coinhibitory receptor downregulation and increased tissue invasiveness", Immunity, 47, pp.848~861 (2017)
132. Muranski P, "Adoptive immunotherapy of cancer using CD4+ T cells", Curr Opin Immunol, 21, pp.200~208 (2009)
133. Hunder NN, "Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1", N Engl J Med, 358, pp.2698~2703 (2008)
134. Xie Y, "Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma", J Exp Med, 207, pp.651~667 (2010)
135. Lu Y, "Th9 cells promote antitumor immune responses in vivo", J Clin Invest, 122, pp.4160~4171 (2012)
136. Végran F, "The transcription factor IRF1 dictates the IL-21-dependent anticancer functions of TH9 cells", Nat Immunol, 15, pp.758~766 (2014)
137. Lee J, "The multifaceted role of Th1, Th9, and Th17 cells in immune checkpoint inhibition therapy", Front Immunol, 12, pp.625667~ (2021)
138. Leonard WJ, "IL-21 signaling in immunity", F1000 Res, 5, pp.224~ (2016)
139. Hinrichs CS, "IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy", Blood, 111, pp.5326~5333 (2008)
140. Spolski R, "Interleukin-21 : a double-edged sword with therapeutic potential", Nat Rev Drug Discov, 13, pp.379~395 (2014)
141. Santegoets SJ, "IL-21 promotes the expansion of CD27+ CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells", J Transl Med, 11, pp.37~ (2013)
142. Xin G, "A critical role of IL-21-induced BATF in sustaining CD8-T-cell-mediated chronic viral control", Cell Reports, 13, pp.1118~1124 (2015)
143. Topchyan P, "Harnessing the IL-21-BATF pathway in the CD8+ T cell anti-tumor response", Cancers(Basel), 13, pp.1263~ (2021)
144. Gaffen SL, "The IL-23-IL-17 immune axis : from mechanisms to therapeutic testing", Nat Rev Immunol, 14, pp.585~600 (2014)
145. Kurachi M, "The transcription factor BATF operates as an essential differentiation checkpoint in early effector CD8+ T cells", Nat Immunol, 15, pp.373~383 (2014)
146. Ciofani M, "A validated regulatory network for Th17 cell specification", Cell, 151, pp.289~303 (2012)
147. Betz BC, "Batf coordinates multiple aspects of B and T cell function required for normal antibody responses", J Exp Med, 207, pp.933~942 (2010)
148. Ise W, "The transcription factor BATF controls the global regulators of class-switch recombination in both B cells and T cells", Nat Immunol, 12, pp.536~543 (2011)
149. Tussiwand R, "Compensatory dendritic cell development mediated by BATF-IRF interactions", Nature, 490, pp.502~507 (2012)
150. Jabeen R, "Th9 cell development requires a BATF-regulated transcriptional network", J Clin Invest, 123, pp.4641~4653 (2013)
151. Sahoo A, "Batf is important for IL-4 expression in T follicular helper cells", Nat Commun, 6, pp.7997~ (2015)
152. Schraml BU, "The AP-1 transcription factor BATF controls TH17 differentiation", Nature, 460, pp.405~409 (2009)
153. Chen Y, "BATF regulates progenitor to cytolytic effector CD8+ T cell transition during chronic viral infection", Nat Immunol, 22, pp.996~1007 (2021)
154. Seo H, "BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells", Nat Immunol, 22, pp.983~995 (2021)
155. Topchyan P, "Spatial transcriptomics demonstrates the role of CD4 T cells in effector CD8 T cell differentiation during chronic viral infection", Cell Reports, 41, pp.111736~ (2022)
156. Cui C, "Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes anti-tumor CD8 T cell responses", Cell, 184, pp.6101~6118 (2021)
157. Jansen CS, "An intra-tumoral niche maintains and differentiates stem-like CD8 T cells", Nature, 576, pp.465~470 (2019)
158. Schumacher TN, "Tertiary lymphoid structures in cancer", Science, 375 (2022)
159. Bindea G, "Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer", Immunity, 39, pp.782~795 (2013)
160. Cillo AR, "Immune landscape of viral-and carcinogen-driven head and neck cancer", Immunity, 52, pp.183~199 (2020)
161. Gu-Trantien C, "CD4+ follicular helper T cell infiltration predicts breast cancer survival", J Clin Invest, 123, pp.2873~2892 (2013)
162. Garaud S, "Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer", JCI Insight, 5, pp.e129641~ (2019)
163. Germain C, "Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer", Am J Respir Crit Care Med, 189, pp.832~844 (2014)
164. Griss J, "B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma", Nat Commun, 10, pp.4186~ (2019)
165. Helmink BA, "B cells and tertiary lymphoid structures promote immunotherapy response", Nature, 577, pp.549~555 (2020)
166. Hennequin A, "Tumor infiltration by Tbet+ effector T cells and CD20+ B cells is associated with survival in gastric cancer patients", OncoImmunology, 5, pp.e1054598~ (2015)
167. Kroeger DR, "Tumor-infiltrating plasma cells are associated with tertiary lymphoid structures, cytolytic T-cell responses, and superior prognosis in ovarian cancer", Clin Cancer Res, 22, pp.3005~3015 (2016)
168. Petitprez F, "B cells are associated with survival and immunotherapy response in sarcoma", Nature, 577, pp.556~560 (2020)
169. Truxova I, "Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients", J Immunother Cancer, 6, pp.139~ (2018)
170. Wieland A, "Defining HPV-specific B cell responses in patients with head and neck cancer", Nature, 597, pp.274~278 (2021)
171. Ruffin AT, "B cell signatures and tertiary lymphoid structures contribute to outcome in head and neck squamous cell carcinoma", Nat Commun, 12, pp.3349~ (2021)
172. Sharonov GV, "B cells, plasma cells and antibody repertoires in the tumour microenvironment", Nat Rev Immunol, 20, pp.294~307 (2020)
173. Sautès-Fridman C, "Tertiary lymphoid structures in cancers : prognostic value, regulation, and manipulation for therapeutic intervention", Front Immunol, 7, pp.407~ (2016)
174. Cho JW, "Dysregulation of TFH-B-TRM lymphocyte cooperation is associated with unfavorable anti-PD-1 responses in EGFR-mutant lung cancer", Nat Commun, 12, pp.6068~ (2021)
175. Luo S, "Chronic inflammation : a common promoter in tertiary lymphoid organ neogenesis", Front Immunol, 10, pp.2938~ (2019)
176. Pitzalis C, "Ectopic lymphoid-like structures in infection, cancer and autoimmunity", Nat Rev Immunol, 14, pp.447~462 (2014)
177. Manzo A, "Secondary and ectopic lymphoid tissue responses in rheumatoid arthritis : from inflammation to autoimmunity and tissue damage", remodeling, 2010, pp.233, 267~285
178. Pipi E, "Tertiary lymphoid structures : autoimmunity goes local", Front Immunol, 9, pp.1952~ (2018)
179. Korpos É, "Identification and characterisation of tertiary lymphoid organs in human type 1 diabetes", Diabetologia, 64, pp.1626~1641 (2021)
180. de Chaisemartin L, "Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer", Cancer Res, 71, pp.6391~6399 (2011)
181. Dieu-Nosjean MC, "Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures", J Clin Oncol, 26, pp.4410~4417 (2008)
182. Bergomas F, "Tertiary intratumor lymphoid tissue in colo-rectal cancer", Cancers(Basel), 4, pp.1~10 (2011)
183. Coppola D, "Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling", Am J Pathol, 179, pp.37~45 (2011)
184. Cabrita R, "Tertiary lymphoid structures improve immunotherapy and survival in melanoma", Nature, 577, pp.561~565 (2020)
185. van Dijk N, "Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer : the NABUCCO trial", Nat Med, 26, pp.1839~1844 (2020)
186. Siliņa K, "Germinal centers determine the prognostic relevance of tertiary lymphoid structures and are impaired by corticosteroids in lung squamous cell carcinoma", Cancer Res, 78, pp.1308~1320 (2018)
187. Cottrell TR, "Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma : a proposal for quantitative immune-related pathologic response criteria(irPRC)", Ann Oncol, 29, pp.1853~1860 (2018)
188. Thommen DS, "A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade", Nat Med, 24, pp.994~1004 (2018)
189. Johansson-Percival A, "De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors", Nat Immunol, 18, pp.1207~1217 (2017)
190. Allen E, "Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation", Sci Transl Med, 9 (2017)
191. Overacre-Delgoffe AE, "Microbiota-specific T follicular helper cells drive tertiary lymphoid structures and anti-tumor immunity against colorectal cancer", Immunity, 54, pp.2812~2824 (2021)
192. Lutz ER, "Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation", Cancer Immunol Res, 2, pp.616~631 (2014)

관련 논문AI추천